This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Baxter Launches Drug Library Guide for Smart Infusion System
by Zacks Equity Research
Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown
by Zacks Equity Research
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.
Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View
by Zacks Equity Research
Quest Diagnostics' (DGX) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate.
Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device
by Zacks Equity Research
Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc.(ISRG) posted adjusted earnings of $4.67 per share in the first quarter of 2017, crushing the Zacks Consensus Estimate of $3.97 on stellar revenue growth.
Mazor (MZOR) Gets FDA Clearance For Mazor X Align Software
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it has received the FDA clearance for its Mazor X Align software.
Quality Systems (QSII) to Acquire Entrada for $34 Million
by Zacks Equity Research
Quality Systems, Inc. announced that it has entered into a deal to acquire Entrada, Inc. for $34 million.
Mazor Robotics (MZOR) Catches Eye: Stock Moves Up 10.2%
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR) moved big last session, as its shares rose over 10% on the day.
Hologic (HOLX) Up 3.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts' (MDRX) dbMotion Solution Available Through Azure
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX), announced that dbMotion Solution will be now available through Microsoft Corporation's (MSFT) cloud computing service Azure.
Accuray TomoTherapy System Starts Cancer Treatment in Africa
by Zacks Equity Research
Accuray Inc. (ARAY) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company's flagship TomoTherapy system.
ResMed's Study Results for Central Sleep Apnea Hold Promise
by Zacks Equity Research
ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).
athenahealth (ATHN) Allies with CoverMyMeds for Faster ePA
by Zacks Equity Research
athenahealth Inc. (ATHN) recently entered into a strategic partnership with CoverMyMeds.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
On Apr 10, we issued an updated research report Denver, CO-based DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure.
Masimo (MASI) Launches Root Platform with Kite Trademark
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system).
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering
by Zacks Equity Research
AngioDynamics, Inc. (ANGO) announced that it has priced its underwritten public offering of 2.35 million shares of common stock.
ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern
by Zacks Equity Research
On Apr 7, we issued an updated research report on Danvers, MA-based ABIOMED, Inc. (ABMD), a leading medical product developer.
Hill-Rom's Innovations Make Surgeries More Safe, Accurate
by Zacks Equity Research
Hill-Rom Holdings, Inc. (HRC) recently demonstrated the impact of surgical patient positioning on skin and nerve pressure-related injuries.
PetMed Faces Concerns over New Order Sales, Competition
by Zacks Equity Research
On Apr 6, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
athenahealth Now a Strong Buy: Should You Add the Stock?
by Zacks Equity Research
On Apr 5, athenahealth (ATHN) was raised to a Zacks Rank #1 (Strong Buy).
Medidata & TESARO Win CARE 'Clinical Partnership' Award
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced the receipt of the 'Clinical Partnership of the Year' award at the second annual Clinical and Research Excellence (CARE) Awards, courtesy of its 'unique technology collaboration' with TESARO.
Omnicell's Aesynt Buyout Looks Promising amid Several Woes
by Zacks Equity Research
On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Crude Bucks Choppy Trend - Dave's Daily Dive
by David Bartosiak
Crude bucked the choppy trend in markets today as equities sloshed back-and-forth most of the day
New Strong Buy Stocks for April 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Hologic Completes Cynosure Buyout, Boosts Core Business
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.